These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 24531711)
21. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer. Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A Front Immunol; 2019; 10():804. PubMed ID: 31105691 [TBL] [Abstract][Full Text] [Related]
22. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer. Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338 [TBL] [Abstract][Full Text] [Related]
23. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression. Kechagioglou P; Papi RM; Provatopoulou X; Kalogera E; Papadimitriou E; Grigoropoulos P; Nonni A; Zografos G; Kyriakidis DA; Gounaris A Anticancer Res; 2014 Mar; 34(3):1387-400. PubMed ID: 24596386 [TBL] [Abstract][Full Text] [Related]
24. Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer. Gasparyan M; Lo MC; Jiang H; Lin CC; Sun D J Biol Chem; 2020 Aug; 295(34):12188-12202. PubMed ID: 32467227 [TBL] [Abstract][Full Text] [Related]
25. Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer. Beg S; Siraj AK; Prabhakaran S; Jehan Z; Ajarim D; Al-Dayel F; Tulbah A; Al-Kuraya KS Breast Cancer Res Treat; 2015 Jun; 151(3):541-53. PubMed ID: 25981902 [TBL] [Abstract][Full Text] [Related]
26. Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer. Steenbrugge J; Vander Elst N; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Dirix L; Van Laere S; Meyer E Front Immunol; 2019; 10():2928. PubMed ID: 31921184 [TBL] [Abstract][Full Text] [Related]
27. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Rigby RJ; Simmons JG; Greenhalgh CJ; Alexander WS; Lund PK Oncogene; 2007 Jul; 26(33):4833-41. PubMed ID: 17297444 [TBL] [Abstract][Full Text] [Related]
28. The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells. Wang X; Zhao J; Huang J; Tang H; Yu S; Chen Y Biochem Biophys Res Commun; 2012 Aug; 425(1):51-7. PubMed ID: 22820191 [TBL] [Abstract][Full Text] [Related]
29. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options. Burnett JP; Korkaya H; Ouzounova MD; Jiang H; Conley SJ; Newman BW; Sun L; Connarn JN; Chen CS; Zhang N; Wicha MS; Sun D Sci Rep; 2015 Nov; 5():15821. PubMed ID: 26522776 [TBL] [Abstract][Full Text] [Related]
30. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells. Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373 [TBL] [Abstract][Full Text] [Related]
31. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas. Zhang GJ; Kimijima I; Abe R; Kanno M; Katagata N; Hara K; Watanabe T; Tsuchiya A Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2329-35. PubMed ID: 9815631 [TBL] [Abstract][Full Text] [Related]
32. Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Chung MJ; Jung SH; Lee BJ; Kang MJ; Lee DG Pathol Int; 2004 Jan; 54(1):10-5. PubMed ID: 14674989 [TBL] [Abstract][Full Text] [Related]
33. p53 in breast cancer subtypes and new insights into response to chemotherapy. Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787 [TBL] [Abstract][Full Text] [Related]
34. Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation. Wang J; Ouyang W; Li J; Wei L; Ma Q; Zhang Z; Tong Q; He J; Huang C Cancer Res; 2005 Aug; 65(15):6601-11. PubMed ID: 16061640 [TBL] [Abstract][Full Text] [Related]
35. SOCS3 methylation in synergy with Reg3A overexpression promotes cell growth in pancreatic cancer. Wang J; Zhou H; Han Y; Liu X; Wang M; Wang X; Yin G; Li X; Xiang M J Mol Med (Berl); 2014 Dec; 92(12):1257-69. PubMed ID: 24996521 [TBL] [Abstract][Full Text] [Related]
36. p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature? Wang X; Stolla M; Ring BZ; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG Hum Pathol; 2016 Sep; 55():196-201. PubMed ID: 27246177 [TBL] [Abstract][Full Text] [Related]
37. [Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and the correlation among them]. Li X; Wang Q; Fu L; Liu M; Yu X Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 40(9):973-8. PubMed ID: 26408616 [TBL] [Abstract][Full Text] [Related]
38. Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. Wu J; Shuang Z; Zhao J; Tang H; Liu P; Zhang L; Xie X; Xiao X Biomed Pharmacother; 2018 Jan; 97():1275-1281. PubMed ID: 29156515 [TBL] [Abstract][Full Text] [Related]
39. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409 [TBL] [Abstract][Full Text] [Related]
40. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]